Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
APREA THERAPEUTICS INC (APRE)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.50-1.96%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for APRE yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Complete $30 million private placement | Aprea raised $30 million in a private placement. | Intact | Private placement raises less than $30 million by 2026-Q1 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
APRE is a speculative, clinical-stage biotechnology company, not a profitable compounder. Its thesis is on watch: APR-1051 development is progressing, but confidence is low and the business remains loss-making.
The evidence snapshot provides no valuation measure or specific market expectations, so whether APRE is cheap or expensive versus peers is unclear. The main expectations hinge on clinical progress and the ability to fund development; the evidence does not show how much of that is reflected in the market.
Near term, losses and elevated risk remain central, even as management has advanced APR-1051 enrollment and dose escalation. Cash rose after a private placement, and management expects it to extend the runway into Q1 2028; operating loss also increased slightly as research spending rose. Clinical data updates are expected in Q4 2026, while a next-call guidance cut and the company’s high miss risk remain concerns.
The multi-year thesis depends on APR-1051 clinical progress and whether future evidence supports further development. ATRN-119 is paused as a solo treatment while management explores combinations, leaving that program’s path less clear. Near-term sector momentum could help sentiment, while weaker jobs data or a guidance cut could add pressure.
Over the next 1 to 3 years, APRE’s setup depends on clinical evidence and financial runway, with meaningful execution and funding risks despite progress on its stated priorities. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in APREA THERAPEUTICS INC's published investment case. The stated target is EPS loss narrows from -$0.83 in 2026 to less negative in 2027. |
| Improving |
| EPS loss worsens beyond -$0.83 in 2026 or -$0.79 in 2027 |
Diluted EPS: $-0.09 per share FY2026-Q3; GAAP. Published target: EPS loss narrows from -$0.83 in 2026 to less negative in 2027. Annual target cannot be compared with a quarterly or TTM observation. Nov 4, 2026-0.09 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Address Nasdaq listing deficiency | If it solves Nasdaq listing issues, it can keep operating. | Under Pressure | Nasdaq delisting due to unresolved deficiency | Stock $0.51 vs $1.00 target Nasdaq notice confirms continued non-compliance with $1.00 minimum bid price rule; stock price remains at $0.51. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.66 → $-0.35 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.66 | $2,263,000 | 3 / 3 |
| 2026-07-25 | $-0.66 | $2,263,000 | 3 / 3 |
| 2026-07-26 | $-0.66 | $2,263,000 | 3 / 3 |
| 2026-07-27 | $-0.66 | $2,263,000 | 3 / 3 |
| 2026-07-28 | $-0.79 | $1,131,500 | 3 / 4 |
| 2026-07-29 | $-0.79 | $1,131,500 | 3 / 4 |
| 2026-07-30 | $-0.79 | $1,131,500 | 3 / 4 |
| 2026-07-31 | $-0.79 | $1,131,500 | 3 / 4 |
| 2026-08-01 | $-0.79 | $1,131,500 | 3 / 4 |
| 2026-08-02 | $-0.79 | $1,131,500 | 3 / 4 |
| 2026-08-03 | $-0.79 | $1,131,500 | 3 / 4 |
| 2026-08-04 | $-0.79 | $1,131,500 | 3 / 4 |
| 2026-08-05 | $-0.79 | $1,131,500 | 3 / 4 |
| 2026-08-06 | $-0.79 | $1,131,500 | 3 / 4 |
| 2026-08-07 | $-0.66 | $2,263,000 | 3 / 3 |
| 2026-08-08 | $-0.79 | $1,131,500 | 3 / 4 |
| 2026-08-09 | $-0.79 | $1,131,500 | 3 / 4 |
| 2026-08-10 | $-0.79 | $1,131,500 | 3 / 4 |
| 2026-08-11 | $-0.79 | $1,131,500 | 3 / 4 |
| 2026-08-12 | $-0.79 | $1,131,500 | 3 / 4 |
| 2026-08-13 | $-0.79 | $1,131,500 | 3 / 4 |
| 2026-08-14 | $-0.66 | $2,263,000 | 3 / 3 |
| 2026-08-15 | $-0.66 | $2,263,000 | 3 / 3 |
| 2026-08-16 | $-0.66 | $2,263,000 | 3 / 3 |
| 2026-08-17 | $-0.66 | $2,263,000 | 3 / 3 |
| 2026-08-18 | $-0.66 | $2,263,000 | 3 / 2 |
| 2026-08-19 | $-0.66 | $2,263,000 | 3 / 3 |
| 2026-08-20 | $-0.27 | $2,263,000 | 3 / 3 |
| 2026-08-21 | $-0.27 | $2,263,000 | 3 / 3 |
| 2026-08-22 | $-0.27 | $2,263,000 | 3 / 3 |
| 2026-08-23 | $-0.27 | $2,263,000 | 3 / 3 |
| 2026-08-24 | $-0.27 | $2,263,000 | 3 / 3 |
| 2026-08-25 | $-0.27 | $2,263,000 | 3 / 3 |
| 2026-08-26 | $-0.27 | $2,263,000 | 3 / 3 |
| 2026-08-27 | $-0.27 | $2,263,000 | 3 / 3 |
| 2026-08-28 | $-0.27 | $2,263,000 | 3 / 3 |
| 2026-08-29 | $-0.27 | $2,263,000 | 3 / 3 |
| 2026-08-30 | $-0.27 | $2,263,000 | 3 / 3 |
| 2026-08-31 | $-0.27 | $2,263,000 | 3 / 3 |
| 2026-09-01 | $-0.27 | $2,263,000 | 3 / 3 |
| 2026-09-02 | $-0.27 | $2,263,000 | 3 / 3 |
| 2026-09-03 | $-0.27 | $2,263,000 | 3 / 3 |
| 2026-09-04 | $-0.27 | $2,263,000 | 3 / 3 |
| 2026-09-05 | $-0.27 | $2,263,000 | 3 / 3 |
| 2026-09-06 | $-0.27 | $2,263,000 | 3 / 3 |
| 2026-09-07 | $-0.27 | $2,263,000 | 3 / 3 |
| 2026-09-08 | $-0.27 | $2,263,000 | 3 / 3 |
| 2026-09-09 | $-0.27 | $2,263,000 | 3 / 2 |
| 2026-09-10 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-09-11 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-09-12 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-09-13 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-09-14 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-09-15 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-09-16 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-09-17 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-09-18 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-09-19 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-09-20 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-09-21 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-09-22 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-09-23 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-09-24 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-09-25 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-09-26 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-09-27 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-09-28 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-09-29 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-09-30 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-10-01 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-10-02 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-10-03 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-10-04 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-10-05 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-10-06 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-10-07 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-10-08 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-10-09 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-10-10 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-10-11 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-10-12 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-10-13 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-10-14 | $-0.29 | $2,263,000 | 2 / 2 |
| 2026-10-15 | $-0.35 | $2,263,000 | 3 / 3 |
| 2026-10-16 | $-0.35 | $2,263,000 | 3 / 3 |
| 2026-10-17 | $-0.35 | $2,263,000 | 3 / 3 |
| 2026-10-18 | $-0.35 | $2,263,000 | 3 / 3 |
| 2026-10-19 | $-0.35 | $2,263,000 | 3 / 3 |
| 2026-10-20 | $-0.35 | $2,263,000 | 3 / 3 |
| 2026-10-21 | $-0.35 | $2,263,000 | 3 / 3 |
| 2026-10-22 | $-0.35 | $2,263,000 | 3 / 3 |
| 2026-10-23 | $-0.35 | $2,263,000 | 3 / 3 |
| 2026-10-24 | $-0.35 | $2,263,000 | 3 / 3 |
| 2026-10-25 | $-0.35 | $2,263,000 | 3 / 3 |
| 2026-10-26 | $-0.35 | $2,263,000 | 3 / 3 |
| 2026-10-27 | $-0.35 | $2,263,000 | 3 / 3 |
| 2026-10-28 | $-0.35 | $2,263,000 | 3 / 3 |
| 2026-10-29 | $-0.35 | $2,263,000 | 3 / 3 |
| 2026-10-30 | $-0.35 | $2,263,000 | 3 / 3 |
| 2026-10-31 | $-0.35 | $2,263,000 | 3 / 3 |
| 2026-11-01 | $-0.35 | $2,263,000 | 3 / 3 |
| 2026-11-02 | $-0.35 | $2,263,000 | 3 / 3 |
| 2026-11-03 | $-0.35 | $2,263,000 | 3 / 3 |
| 2026-11-04 | $-0.35 | $2,263,000 | 3 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.